Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics (ACRS)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics (ACRS)

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts

January 8, 2018 7:00 AM EST

Highly statistically significant results on all primary and secondary endpointsStatistical significance seen as early as day 28, after 4 weeks of treatment in WART-203If approved, A-101 45% would be the first FDA approved treatment for common warts

MALVERN, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to... More